Authors: Ursin, G Parisky, YR Pike, MC Spicer, DV

Citation: G. Ursin et al., Mammographic density changes during the menstrual cycle, CANC EPID B, 10(2), 2001, pp. 141-142

Authors: Gram, IT Ursin, G Spicer, DV Pike, MC

Citation: It. Gram et al., Reversal of gonadotropin-releasing hormone agonist induced reductions in mammographic densities on stopping treatment, CANC EPID B, 10(11), 2001, pp. 1117-1120

Authors: Spicer, DV Pike, MC

Citation: Dv. Spicer et Mc. Pike, Future possibilities in the prevention of breast cancer - Luteinizing hormone-releasing hormone agonists, BREAST CA R, 2(4), 2000, pp. 264-267

Authors: Pike, MC Spicer, DV

Citation: Mc. Pike et Dv. Spicer, Hormonal contraception and chemoprevention of female cancers, ENDOCR-R CA, 7(2), 2000, pp. 73-83

Authors: Roberts, JD Shibata, S Spicer, DV McLeod, HL Tombes, MB Kyle, B Carroll, M Sheedy, B Collier, MA Pithavala, YK Paradiso, LJ Clendeninn, NJ

Citation: Jd. Roberts et al., Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks, CANC CHEMOT, 45(5), 2000, pp. 423-427

Authors: Roberts, JD Poplin, EA Tombes, MB Kyle, B Spicer, DV Grant, S Synold, T Moran, R

Citation: Jd. Roberts et al., Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation, CANC CHEMOT, 45(2), 2000, pp. 103-110